Business
BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer
24% ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100) The combination demonstrated a favorable safety and tolerability profile Results ...
About this update from Bioinvent International Ab
[{"type":"list","items":[{"val":[{"type":"text","content":"24% ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)","length":166,"tagName":"p"}]},{"val":[{"type":"text","content":"The combination demonstrated a favorable safety and tolerability profile","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Results suggest that this combination could deliver a new immuno-oncology option for this population with high unmet need","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"BioInvent will expand the ovarian cancer cohort by enrolling an additional 20 patients focusing on high-grade serous and clear cell subtypes, expected data read-out H2 2026","length":172,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":531,"olType":false},{"type":"text","content":"LUND, SE / ACCESS Newswire / January 5, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced encouraging interim results from its ongoing Phase 2a signal-seeking study evaluating BI-1808, a novel immuno-oncology candidate, in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA ® (pembrolizumab) in patients with recurrent ovarian cancer who have progressed following platinum-based therapy. The interim data from the signal-seeking cohort of patients with recurrent ovarian cancer demonstrates an overall response rate (ORR) of 24%, which represents a meaningful improvement over pembrolizumab monotherapy.","length":848,"tagName":"p"},{"type":"text","content":"Treatment of recurrent ovarian cancer remains one of the most challenging in oncology, with limited treatment options after platinum failure and historically low response rates to immunotherapy. Preclinical studies demonstrated synergistic anti-tumor activity when BI-1808 was combined with pembrolizumab, providing a strong rationale for advancing this combination into clinical development. Ovarian cancer is an exciting prospect for the combination Phase 2a signal-seeking cohort given a complete response (CR) was observed in a platinum-resistant patient treated with BI-1808 mon...